Presentation is loading. Please wait.

Presentation is loading. Please wait.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

Published byRosalia Kok Modified over 6 years ago

Similar presentations

Presentation on theme: "An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke."— Presentation transcript:

1 An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary? 
Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke Ylstra, PhD, Mark A. van de Wiel, PhD, Paul P. Eijk, MSc, Marinus A. Paul, MD, PhD, Egbert F. Smit, Prof, MD, PhD, Pieter E. Postmus, Prof, MD, PhD  Journal of Thoracic Oncology  Volume 7, Issue 8, Pages e3-e5 (August 2012) DOI: /JTO.0b013e31825bcead Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Hematoxylin and eosin stain of biopsy from first (A) and ­second (B) SCLC are shown with CD56 immunohistochemical staining on first (C) and second (D) SCLC. SCLC, small-cell lung cancer. Journal of Thoracic Oncology 2012 7, e3-e5DOI: ( /JTO.0b013e31825bcead) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 Chromosomal aberrations as detected by array CGH for both SCLC biopsies are shown. On the y axis is the log2 tumor to normal ratio and on the x axis the chromosomal position in bp. Gray dots are individual array measurements (105K in total) and red lines, their segmented values. Gain and loss are positive and negative log2 ratio, respectively. All array data are available in the GEO database (GSE16575). SCLC, small-cell lung cancer. Journal of Thoracic Oncology 2012 7, e3-e5DOI: ( /JTO.0b013e31825bcead) Copyright © 2012 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke."

Similar presentations

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.

Primary Small Cell Carcinoma of the Esophagus Jima Lv, MD, Jun Liang, MD, Jinwan Wang, MD, Luhua Wang, MD, Jie He, MD, Zefen Xiao, MD, Weibo Yin, MD Journal.
Primary Mucoepidermoid Carcinoma of the Esophagus

Primary Mucoepidermoid Carcinoma of the Esophagus
High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis  Robert A.A. van Boerdonk, MSc, Johannes.

High-Risk Human Papillomavirus–Positive Lung Cancer: Molecular Evidence for a Pattern of Pulmonary Metastasis  Robert A.A. van Boerdonk, MSc, Johannes.
Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.
Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,

Antibody Independent Microfluidic Cell Capture of Circulating Tumor Cells for the Diagnosis of Cancer  Eric Lim, MB, ChB, MD, MSc, FRCS, Andee Tay, BSc,
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.

Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met–Amplified Adenocarcinoma of the.
Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.

Outcomes of Second-Line Chemotherapy in Patients with Relapsed Extensive Small Cell Lung Cancer  Sandra Froeschl, MD, Garth Nicholas, MD, FRCPC, Victor.
Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F

Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F
Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K

Timon P. H. Buys, BSc, Sarit Aviel-Ronen, MD, Thomas K
Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.

Dramatic Response to Low-Dose Erlotinib of Epidermal Growth Factor Receptor Mutation-Positive Recurrent Non-small Cell Lung Cancer After Severe Cutaneous.
An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.

An 82-Year-Old Woman With Small-Cell Lung Cancer: Relapse After 9 Years or a New Primary?  Martijn R. Groenendijk, MD, Erik Thunnissen, MD, PhD, Bauke.
The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming.

The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming.
Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.

Epidermal Growth Factor Receptor Mutations in Small Cell Lung Cancer: A Brief Report  Tsu-Hui Shiao, MD, Yih-Leong Chang, MD, Chong-Jen Yu, MD, PhD, Yeun-Chung.
KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.

KRAS Mutation Analysis Helps to Differentiate Between Pulmonary Metastasis from Colon Adenocarcinoma In Situ and Primary Lung Adenocarcinoma  Taylor M.
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,

Similar presentations

Ads by Google